Efsubaglutide Alfa
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
Shanghai Yinnuo Pharmaceutical Technology Co · Phase 2/3 · Active, not recruiting · Enrollment 1003
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Phase IIb:Efsubaglutide Alfa 5 mg QW | n/r | n/r | n/r | n/r | n/r |
| Phase IIb:Efsubaglutide Alfa 10 mg QW | n/r | n/r | n/r | n/r | n/r |
| Phase IIb:Efsubaglutide Alfa 20 mg QW | n/r | n/r | n/r | n/r | n/r |
| Phase IIb:Efsubaglutide Alfa 20 mg Q2W | n/r | n/r | n/r | n/r | n/r |
| Phase IIb:Placebo | n/r | n/r | n/r | n/r | n/r |
| Phase III:Recommended Phase 3 Dose (RP3D) Low Dose QW | n/r | n/r | n/r | n/r | n/r |
| Phase III:Recommended Phase 3 Dose (RP3D) High Dose QW | n/r | n/r | n/r | n/r | n/r |
| Phase III:Recommended Phase 3 Dose (RP3D) High Dose Q2W | n/r | n/r | n/r | n/r | n/r |
| Phase III:Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.